KalshiScience and Technology
When will the FDA approve Intellia Therapeutics' lonvo-z?
Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
Ends Jul 1, 2027
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
- Before July 20274.2K VOL.Yes 58%No 42%58¢
- Before October 20271K VOL.Yes 85%No 15%85¢
- Before 2028610.8 VOL.Yes 72%No 28%72¢
Rules Summary
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.
Timeline and Payout
- Opened
- Mar 24, 2026, 2:00 PM
- Closes
- Jul 1, 2027, 3:59 AM
- Pays out
- 0.5 hours after close
Series KXFDAAPPROVALDATENTLA · Event KXFDAAPPROVALDATENTLA-LONV · Market KXFDAAPPROVALDATENTLA-LONV-27JUL01